drugset / Trial / NCT05696548
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Phase 2
Active not recruiting
51 enrolled
National Cancer Center Hospital East
Ono Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
Timeline
- Start
- 2019-07-02
- Primary completion
- 2025-09-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |